the role of analytics in the development of advanced ... · n287 0.4% 0.1% 0.2% 0.6% 1.2% 1.2% n316...

23
1 Biogen | Confidential and Proprietary The Role of Analytics in the Development of Advanced Process Controls (APC) Patrick Swann, Ph.D. September 6, 2016

Upload: others

Post on 30-Jan-2021

5 views

Category:

Documents


0 download

TRANSCRIPT

  • 1Biogen | Confidential and Proprietary

    The Role of Analytics in the Development of Advanced Process Controls (APC)Patrick Swann, Ph.D.September 6, 2016

  • 2Biogen | Confidential and Proprietary

    Specifications are “one part” of an overall Control Strategy

  • 3Biogen | Confidential and Proprietary

    APC can enable an Attribute-Based Control Strategy

    Improved use of analytics allows focus on specific quality attributes in-process and use of known levers for process controlAn attribute-targeted control strategy using APC can lead to more efficient and effective controlsMore efficient controls can improve availabilityMore effective controls can improve quality assurance

  • 4Biogen | Confidential and Proprietary

    Product Complexity

  • 5Biogen | Confidential and Proprietary

    Traditional Approach - Charge VariantsIEC

    Abso

    rban

    ce

    -0.02

    0.00

    0.02

    0.04

    0.06

    0.08

    0.10

    0.12

    0.14

    0.16

    0.18

    0.20

    0.22

    0.24

    0.26

    0.28

    Minutes6.00 6.10 6.20 6.30 6.40 6.50 6.60 6.70 6.80 6.90 7.00 7.10 7.20 7.30 7.40 7.50 7.60 7.70 7.80 7.90 8.00 8.10 8.20 8.30 8.40 8.50 8.60 8.70 8.80 8.90

    Acidic isoforms

    Main isoforms

    Basic isoforms

    Marker

    Imaging Capillary IEF of an IgG1 Monoclonal Antibody

    cIEF

    Slide courtesy of Li Zang, Biogen Analytical Development

  • 6Biogen | Confidential and Proprietary

    Product Characterization - Acidic Fraction Collection

    • Free Flow Electrophoresis

    IEF based separation, direct correlation of fractions with cIEF peaks

    • Fractionation of monoclonal antibody acidic species into 3-4 sub-species

    6 http://www.ffeservice.com/index.php/technology.htmlSlide courtesy of Li Zang, Biogen Analytical Development

  • 7Biogen | Confidential and Proprietary

    Abso

    rban

    ce

    -0.02

    0.00

    0.02

    0.04

    0.06

    0.08

    0.10

    0.12

    0.14

    0.16

    0.18

    0.20

    0.22

    0.24

    0.26

    0.28

    0.30

    0.32

    0.34

    0.36

    0.38

    0.40

    Minutes5.50 5.60 5.70 5.80 5.90 6.00 6.10 6.20 6.30 6.40 6.50 6.60 6.70 6.80 6.90 7.00 7.10 7.20 7.30 7.40 7.50 7.60 7.70 7.80 7.90 8.00 8.10 8.20 8.30 8.40 8.50 8.60 8.70 8.80 8.90 9.00

    Acidic Fractions Collected by FFE

    DSMain peakAcidic fraction 1Acidic fraction 2Acidic fraction 3Acidic fraction 4

    Slide courtesy of Li Zang, Biogen Analytical Development

  • 8Biogen | Confidential and Proprietary

    Asparagine Deamidation

    1 2 3 4

    N287 0.4% 0.1% 0.2% 0.6% 1.2% 1.2%

    N316 2.8% 0.7% 2.7% 6.1% 7.2% 7.6%

    N362 0.1% 0.1% 0.1% 0.2% 0.2% 0.2%

    N385, N390 4.6% 1.4% 1.8% 8.5% 8.1% 8.5%

    Trend

    Heavy Chain

    Acidic FractionsDS

    Main Peak

    DeamidationChain

    DS

    Slide courtesy of Li Zang, Biogen Analytical Development

  • 9Biogen | Confidential and Proprietary

    Isoforms DS Main Peak Acidic Fractions1 2 3 4

    Light ChainCML (+ 58 Da) ND ND ND 0.4% 0.7% 1.0%Glycation (+162 Da) 0.6% 1.1% 0.6% 1.1% 0.7% 3.2%N-Glucuronyl (+176 Da) 0.4% ND 0.3% 1.0% 1.0% 0.3%

    Heavy Chain

    CML (+ 58 Da) 1.2% ND 1.4% 2.9% 3.9% 3.6%+ 79-90 Da 0.8% ND 0.5% 1.5% ND ND+ 111-116 Da 0.6% ND 0.6% ND 1.8% ND+ 121-123 Da ND ND ND 0.7% ND ND+ 132 -137 Da 0.6% ND ND ND 1.1% 0.9%Glycation (+162 Da) 3.1% 1.9% 4.1% 3.1% 3.3% 3.0%N-Glucuronyl (+176 Da) 1.1% ND 1.2% 7.2% 7.2% 7.6%Total impurity 6.4% 3.0% 8.7% 17.9% 19.7% 19.6%

    Impurity Level by Reduced Intact Mass

    Slide courtesy of Li Zang, Biogen Analytical Development

  • Published in: David R. Bush; Li Zang; Arseniy M. Belov; Alexander R. Ivanov; Barry L. Karger; Anal. Chem. 2016, 88, 1138-1146.DOI: 10.1021/acs.analchem.5b03218Copyright © 2015 American Chemical Society

  • 11Biogen | Confidential and Proprietary

    Protein Modifications in Acidic Species

    Ref: Du, Y., et al. "Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies." MAbs 4(5).

    Slide courtesy of Li Zang, Biogen Analytical Development

    PTM complexity at individual amino acid level >> separatory capability

    An attribute-based control strategy can leverage chemical knowledge about factors that cause formation of these modifications Y = f(x)

  • 12Biogen | Confidential and Proprietary

    The way forward

  • 13Biogen | Confidential and Proprietary

    Biotech Manufacture – High Level Model

    Product Quality

    Process Input

    Proc

    ess

    Process Control • Robust process design • Advanced process control

    Raw Material

    RM Control• Screening and/or • Control by Vendor• Learn from MFG experience

  • 14Biogen | Confidential and Proprietary

    APC Key Concepts

    Process Analytical TechnologyA system for designing, analyzing, and controlling manufacturing through timely

    measurements (i.e., during processing)

    of critical quality and performance

    attributes of raw and in-process materials

    and processes with the goal of ensuring

    final product quality.

    At-line

    In-line

    On-line

    Slide courtesy of Bassam Nakhle, Biogen Analytical Development

  • 15Biogen | Confidential and Proprietary

    APC Key Concepts

    DS DP

    Real Time Release Testing (RTRT)The ability to evaluate and ensure the quality of in-process and/or final product based on process data, which typically include a valid combination of measured material attributes and process controls.

    Slide courtesy of Bassam Nakhle, Biogen Analytical Development

  • 16Biogen | Confidential and Proprietary

    APC applied to Biotech Manufacture

  • 17Biogen | Confidential and Proprietary

    15kL3750L950L

    Seed train

    Production Reactor Harvest

    Raw Materials

    Purification Filling

    DS R

    elease

    DS• Endotoxin• Bioburden• Potency

    APC for Biotech Drug Substance

    In-line: protein concentrationAt line: purity, aggregation,

    charge variants

    Raw Materials• Geneology• Spectroscopic tools• Rapid ID testing

    Media/buffer Prep control

    UF/DF: in-line Protein concentration

    Bioreactor: in-line Raman, capacitance

    feedback feedback

    Feed forward

    Bioreactor and/or harvest:At line multi-attribute testing and/or CQA Predictive models for feedforward control

    http://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjIs9j4sbPKAhXLbT4KHV6XBJUQjRwIBw&url=http://mohali.all.biz/mixing-tank-g343888&psig=AFQjCNF-pMkbyVtS0dboSv-LQTcefVIEig&ust=1453207500280756http://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjIs9j4sbPKAhXLbT4KHV6XBJUQjRwIBw&url=http://mohali.all.biz/mixing-tank-g343888&psig=AFQjCNF-pMkbyVtS0dboSv-LQTcefVIEig&ust=1453207500280756

  • 18Biogen | Confidential and Proprietary

    Bioreactor Capture Polish 1 Polish 2 DrugSub.

    Drug Prod.

    Sialic acid

    Deamid-ation

    Trisulfidebonds

    High mannose

    Glycation

    AGE

    Fragments

    Met X oxidation

    Etc….

    Critical Control Point - a step at which control can be applied and is essential to prevent or eliminate a hazard or reduce it to an acceptable level (ASTM E2590).

    Possible Control Points for Charge-Related Attributes

  • 19Biogen | Confidential and Proprietary

    High-Throughput Peptide Map Workflow

    30min gradient

    Pepfinder, automatic peptide identification

    1 2

    34

    Targeted peptide quantitation

    Bravo ProA purification (60 min/batch)

    Lys-C digestion or rapid trypsin digestion (1-2 hr)

    LC –MS analysis, 30 min/sample

    Data analysis, 0.5 hr/sample

    In-house writtenExcel Script

    50-100 µg protein digest

    Slide courtesy of Zoran Sosic, Biogen Analytical Development

  • 20Biogen | Confidential and Proprietary

    2-AA analysis (routine)

    Peptide Mapping

    Flu

    ore

    scence

    0.00

    100.00

    200.00

    300.00

    400.00

    500.00

    600.00

    Minutes0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00

    BiN

    A0

    BiN

    A0-

    Gal

    BiN

    A0-

    2Gal

    Mon

    osia

    lylg

    lyca

    ns

    Correlation of %Galactosylation with 2-AA

    Slide courtesy of Zoran Sosic, Biogen Analytical Development

  • 21Biogen | Confidential and Proprietary

    Controlling Glycation via Glucose

    21

    Low glucose feedback control

    High glucose feedback control

    Slide – JP Smelko. Data courtesy of Brandon Berry and Terrence Dobrowsky

    Glycation = f ([glucose], time, …)

  • 22Biogen | Confidential and Proprietary

    Summary & ConclusionsWhen product complexity is greater than analytical specificity, end-product testing alone is not an attribute-based control strategy

    High throughput and selective methods applied to process intermediates can improve process understanding

    This process understanding allows a focus on known “levers” (critical control points and critical process parameters) for more efficient and effective controls of product quality attributes

    Attribute = f (x1, x2 ,…)

  • 23Biogen | Confidential and Proprietary

    AcknowledgementsRohin Mhatre – Regulatory Affairs

    Brian Fahie – Analytical Development• Li Zang• Zoran Sosic• Bassam Nakhle

    Eliana D. Clark – Manufacturing Sciences

    John Paul Smelko – Cell Culture Development

    The Role of Analytics in the Development of Advanced Process Controls (APC)Specifications are “one part” of an overall Control StrategyAPC can enable an Attribute-Based Control StrategyProduct ComplexityTraditional Approach - Charge Variants�IECProduct Characterization - Acidic Fraction CollectionAcidic Fractions Collected by FFE Asparagine DeamidationImpurity Level by Reduced Intact MassSlide Number 10Protein Modifications in Acidic SpeciesThe way forwardBiotech Manufacture – High Level ModelAPC Key ConceptsAPC Key ConceptsAPC applied to Biotech ManufactureSlide Number 17Critical Control Point - a step at which control can be applied and is essential to prevent or eliminate a hazard or reduce it to an acceptable level (ASTM E2590).High-Throughput Peptide Map WorkflowSlide Number 20Controlling Glycation via GlucoseSummary & ConclusionsAcknowledgements